Hoffmann, Markus http://orcid.org/0000-0003-4603-7696
Arora, Prerna
Nehlmeier, Inga http://orcid.org/0000-0002-8752-7491
Kempf, Amy
Cossmann, Anne
Schulz, Sebastian R. http://orcid.org/0000-0001-6554-3346
Morillas Ramos, Gema
Manthey, Luis A.
Jäck, Hans-Martin http://orcid.org/0000-0002-6332-8463
Behrens, Georg M. N. http://orcid.org/0000-0003-3111-621X
Pöhlmann, Stefan http://orcid.org/0000-0001-6086-9136
Funding for this research was provided by:
Deutsches Zentrum für Infektionsforschung (80018019238)
EC | European Regional Development Fund (Defeat Corona, ZW7-8515131)
Bundesministerium für Bildung und Forschung (01KI20328A, 01KX2021)
Niedersächsische Ministerium für Wissenschaft und Kultur (14-76103-184, COFONI Network, including projects 7FF22, 6FF22, 10FF22)
European Commission (project UNDINE)
Deutsche Forschungsgemeinschaft (PO 716/11-1, PO 716/14-1)
Article History
Received: 15 February 2023
Accepted: 18 February 2023
First Online: 3 March 2023
Competing interests
: S.P. and M.H. conducted contract research (testing of vaccine sera for neutralizing activity against SARS-CoV-2) for Valneva unrelated to this work. G.M.N.B. served as an advisor for Moderna and S.P. served as an advisor for BioNTech, unrelated to this work. All other authors declare no competing interests.